Affinium Pharmaceuticals, Ltd. Announces the Initiation of a Phase I ClinicalTrial Using an Oral Formulation of AFN-1252

15-Apr-2010 - USA
Affinium Pharmaceuticals announced the commencement of a Phase I study in the United States for its novel molecular entity, AFN-1252, a first in class antibiotic candidate focused on the oral and IV treatment of susceptible and highly resistant strains of Staphylococcus aureus (MRSA). The study will evaluate the safety and tolerability of a new, oral tablet formulation. Dr. Barry Hafkin, Chief Medical Officer of Affinium Pharmaceuticals, noted, "We have previously documented good oral bioavailability and excellent tolerability of the drug candidate in two previous clinical studies using simple oral formulations, and we are very pleased to move a newly developed oral formulation that we expect will optimize the pharmacokinetic profile of AFN-1252. We anticipate that the trial will be completed in the third quarter of this year, and that AFN-1252 will continue to demonstrate the excellent tolerability and safety seen in previous studies."

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances